BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24500315)

  • 1. [Current status and future direction of definitive chemoradiotherapy for esophageal cancer].
    Ito Y
    Nihon Shokakibyo Gakkai Zasshi; 2014 Feb; 111(2):260-8. PubMed ID: 24500315
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current surgical treatment and perspectives for esophageal cancer].
    Tsubosa Y
    Nihon Shokakibyo Gakkai Zasshi; 2014 Feb; 111(2):269-75. PubMed ID: 24500316
    [No Abstract]   [Full Text] [Related]  

  • 3. RTOG 0529: Intensity modulated radiation therapy and anal cancer, a step in the right direction?
    Herman JM; Thomas CR
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):8-10. PubMed ID: 23582245
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
    Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
    Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
    Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
    Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoradiotherapy and surgery for T4 esophageal cancer in Japan.
    Akutsu Y; Matsubara H
    Surg Today; 2015 Nov; 45(11):1360-5. PubMed ID: 25583206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
    Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
    World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
    Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.
    Hamamoto Y; Mizusawa J; Katayama H; Nakamura K; Kato K; Tsubosa Y; Ishikura S; Igaki H; Shinoda M; Fukuda H; Kitagawa Y; Ando N
    Jpn J Clin Oncol; 2016 Apr; 46(4):389-92. PubMed ID: 26830150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
    Suh YG; Lee IJ; Koom WS; Cha J; Lee JY; Kim SK; Lee CG
    Jpn J Clin Oncol; 2014 Jun; 44(6):534-40. PubMed ID: 24771865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.
    Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):449-55. PubMed ID: 25544126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
    Bascoul-Mollevi C; Gourgou S; Galais MP; Raoul JL; Bouché O; Douillard JY; Adenis A; Etienne PL; Juzyna B; Bedenne L; Conroy T
    Eur J Cancer; 2017 Oct; 84():239-249. PubMed ID: 28829992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
    Modesto A; Dalmasso C; Lusque A; Vieillevigne L; Izar F; Moyal E; Carrère N; Guimbaud R; Rives M
    Cancer Radiother; 2020 Apr; 24(2):88-92. PubMed ID: 32156457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Case of Salvage Chemoradiotherapy for Regional Recurrence after Curative Esophagectomy].
    Yamamoto M; Okuno T; Imanishi T; Kanaji S; Yamashita K; Kanemitsu K; Sumi Y; Nakamura T; Suzuki S; Kakeji Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1457-9. PubMed ID: 26805062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients.
    Jingu K; Matsushita H; Takeda K; Narazaki K; Ariga H; Umezawa R; Sugawara T; Miyata G; Onodera K; Nemoto K; Yamada S
    Dis Esophagus; 2013 Jul; 26(5):522-7. PubMed ID: 22925398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and efficacy of concurrent chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: a respective study of 116 cases from a single institution.
    Li X; Zhao LJ; Liu NB; Zhang WC; Pang QS; Wang P; Yuan ZY
    Asian Pac J Cancer Prev; 2015; 16(4):1463-9. PubMed ID: 25743816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
    Lund M; Alexandersson von Döbeln G; Nilsson M; Winter R; Lundell L; Tsai JA; Kalman S
    Radiat Oncol; 2015 Jan; 10():16. PubMed ID: 25582305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.